ELISA Kit for Nitric Oxide Synthase 2, Inducible (NOS2)
SEA837HU
Product group Assays
Product SEA837HU is not available
Product not available
There may be an alternative product available, please contact our technical support team.
Overview
- SupplierCloud-Clone Corp.
- Product NameELISA Kit for Nitric Oxide Synthase 2, Inducible (NOS2)
- Delivery Days Customer12
- ApplicationsELISA
- Assay Detection Range0.156-10ng/mL
- Assay PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Nitric Oxide Synthase 2, Inducible (NOS2) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with...
- Assay SensitivityThe minimum detectable dose of this kit is typically less than 0.055ng/mL
- Assay Test PrincipleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Nitric Oxide Synthase 2, Inducible (NOS2). Standards or samples are then added to the...
- Assay Time3h
- CertificationResearch Use Only
- UNSPSC41116100
- SpeciesHuman
References
- The Effects of Intermittent Hypoxic-Hyperoxic Exposures on Lipid Profile and Inflammation in Patients With Metabolic Syndrome. Afina AB et al., 2021, Front Cardiovasc MedRead this paper
- Whole-Body Cryotherapy Increases the Activity of Nitric Oxide Synthase in Older Men. Wiecek M et al., 2021 Jul 16, BiomoleculesRead this paper
- Targeting NF-kappaB mediated cell signaling pathway and inflammatory mediators by 1,2-diazole in A549 cells in vitro. Vinod Prabhu V et al., 2021 Mar, Biotechnol Rep (Amst)Read this paper
- Correlation analysis of the proportion of monocytic myeloid-derived suppressor cells in colorectal cancer patients. Shirasuna K et al., 2020, PLoS OneRead this paper
- Circulating CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease. Yin J et al., 2016 Jul, Cancer MedRead this paper

